A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients

Summary

The primary objective of this study is to investigate efficacy and safety of SPM 962 in advanced Parkinson's Disease (PD) patients in a multi-center, placebo-controlled study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12 weeks of dose titration/maintenance period). Recommended maintenance dose range is also to be investigated with distribution of the maintenance dose and accumulated response rate of efficacy.

Timeline

Start

2006-08

Primary completion

2008-04

Completion

2008-04

Drugs

Indications